Introduction: Merkel cells are afferent sensory receptors found right below the epidermis (top layer of skin) that function as mechanoreceptors (1). Merkel cell carcinoma (MCC), which was first described in 1972 by Toker as a trabecular skin carcinoma, is a rare and aggressive type of skin cancer with neuroendocrine origin and accounts for less tha

Introduction Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. This case study presents a hypothetical patient, John Doe, a 65-year-old male diagnosed with newly diagnosed multiple myeloma (NDMM). The study outlines his family history, symptoms, diagnosis, treatment,

Introduction The study aimed to evaluate the efficacy of a combination therapy (isatuximab, carfilzomib, lenalidomide, and dexamethasone, referred to as Isa-KRd) in patients with newly diagnosed multiple myeloma (NDMM) who are classified as high-risk. High-risk patients often have poor outcomes, and achieving minimal residual disease (MRD) negativi

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approves First Long-Acting Injectable PrEP with 6-Month Protection The FDA has approved the first twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis in adults and adolescents weighing at least 35 kg. This long

Introduction Primary Myelofibrosis (PMF) is a rare clonal myeloproliferative neoplasm characterised by bone marrow fibrosis, extramedullary hematopoiesis, anaemia, and splenomegaly (1). It can present with nonspecific symptoms and may mimic other chronic conditions such as liver cirrhosis (1). Case Presentation A 64-year-old male was admitted for p

Introduction: The MANIFEST-2 trial is a pivotal phase 3 study evaluating the combination of pelabresib, a bromodomain and extraterminal domain (BET) inhibitor, with ruxolitinib, a Janus kinase (JAK) inhibitor, in patients with myelofibrosis who have not previously received JAK inhibitor therapy (1). Myelofibrosis is a progressive haematological mal

Pelabresib Constellation Pharmaceuticals Inhibitor 0610 (CPI-0610) is an investigational oral BET inhibitor that targets transcriptional regulators involved in myelofibrosis (1). It modulates megakaryocyte differentiation, proliferation, and reduces proinflammatory cytokine expression via the Nuclear Factor kappa-light-chain (NF-κB) pathway (1). BE

Introduction Renal cell carcinoma (RCC) is the most common form of kidney cancer in adults, and a large proportion of patients present with advanced disease. Prognostically, approximately 75% of patients with advanced RCC fall into intermediate or poor-risk categories based on the International Metastatic RCC Database Consortium (IMDC) model. For y

Patient Profile Name: Mr. Michael Harris Age: 61 Sex: Male Occupation: Retired civil engineer Diagnosis: Chronic myeloid leukemia in chronic phase (CML-CP), Philadelphia chromosome-positive BCR: ABL1 Transcript: e14a2 (b3a2) Clinical History & Treatment Background Mr. Harris presented with persistent fatigue, unintentional weight loss, and discomfo